Priya Singh, Alok Kumar Pandey, Swati Rathore, Prashant Sahu and Sushil Kashaw
Dr H S Gour Central University, India
Posters-Accepted Abstracts: Nat Prod Chem Res
Phosphodiesterse (PDE) enzymes are responsible for the hydrolysis of Cyclic Adenosine Monophosphate (c-AMP) and Cyclic Guanosine Monophosphate (c-GMP). They are classified into 11 major families and the type-4 Phosphodiesterase (PDE4) is a c-AMP specific phophodiesterase localized in airway smooth muscle cells as well as in immune and inflammatory cells. Inhibition of PDE4 results in the elevation of c-AMP in these cells, which in turn down-regulates the inflammatory response. COPD is a generic term that embraces several debilitating inflammatory pathologies that often co-exist and is characterized by a slowly progressive and largely irreversible decrement in lung function. There are no drugs that can resolve the underlying inflammation in COPD; even the efficacy of glucocorticoids is controversial. Recently, there has been much interest in PDE4 inhibitors for COPD, which are predicted to alleviate the neutrophilic inflammation associated with this generic disorder. Unfortunately, the effects of prototype PDE4 inhibitors have been compromised by side effects such as nausea, emesis and gastrointestinal disorders. Several companies have focused on the design of a new generation of PDE4 inhibitors dissociating beneficial activity and adverse effects.
Email: Priyasingh6734@gmail.com
